Mesenchymal stem cell therapy - Bioinova

Drug Profile

Mesenchymal stem cell therapy - Bioinova

Alternative Names: AMSC; Autologous mesenchymal stem cell therapy - Bioinova

Latest Information Update: 26 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioinova
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Intervertebral disc degeneration; Shoulder injuries

Most Recent Events

  • 26 Dec 2016 Mesenchymal stem cell therapy is still in phase II trials for Intervertebral disc degeneration in Czech Republic (Bioinova website, December 2016)
  • 09 Oct 2014 Bioinova completes a phase II trial in Shoulder injuries (rotator-cuff tear) in Czech Republic (EudraCT2010-024664-17) prior to October 2014
  • 24 Aug 2013 Phase-II clinical trials in Intervertebral-disc-degeneration in Czech Republic (Parenteral) (EudraCT2010-024665-52)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top